Compassionate Use of Certolizumab Pegol in Patients with Crohn's Disease Who Have Failed Previous TNF Inhibitor Therapies

被引：0
|
作者：
Vermeire, Severine [1 ]
Howaldt, Stefanie
Hommes, Daan [2 ]
Bressler, Brian [3 ]
Colombel, Jean-Frederic [4 ]
Mitchev, Krassimir [5 ]
Rutgeerts, Paul [1 ]
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Leiden Univ, Leiden, Netherlands
[3] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada
[4] Hop Claude Huriez, Lille, France
[5] UCB, Briane Lalleud, Belgium
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2010年 / 105卷
关键词：
D O I：
10.14309/00000434-201010001-01149
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1149
引用
收藏
页码：S416 / S416
页数：1
相关论文
共 50 条
  • [41] The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease
    Schwartz, David A.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 125 - 128
  • [42] Benefit-Risk Assessment of the TNF-Antagonists Adalimumab and Certolizumab Pegol for Maintenance Treatment of Crohn's Disease
    Colombel, Jean-Frederic
    Panaccione, Remo
    Robinson, Anne
    Thakkar, Roopal
    Huang, Bidan
    Pollack, Paul F.
    GASTROENTEROLOGY, 2011, 140 (05) : S774 - S774
  • [43] Regain of Response and Remission by Dose Adjustment in Patients with Crohn's Disease Who Responded to Certolizumab Pegol: Results from the WELCOME Study
    Sandborn, William
    D'Haens, Geert
    Vermeire, Severine
    Colombel, Jean-Frederick
    Fedorak, Richard
    Spehlmann, Martina
    Wolf, Douglas
    Mitchev, Krassimir
    Jamoul, Corinne
    Abreu, Maria
    Rutgeerts, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S450 - S451
  • [44] Long-Term Remission With Certolizumab Pegol in Crohn's Disease: Efficacy Over 4 Years in Patients With NO Prior TNF-α Inhibitor Exposure (PRECiSE 3 Study)
    Lichtenstein, Gary
    Thomsen, Ole O.
    Schreiber, Stefan
    Lawrance, Ian C.
    Hanauer, Stephen B.
    Bloomfield, Ralph
    Sandborn, William J.
    GASTROENTEROLOGY, 2010, 138 (05) : S165 - S165
  • [45] Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn’s Disease: Results of a Decision Analysis
    Ashwin N. Ananthakrishnan
    Chin Hur
    Joshua R. Korzenik
    Digestive Diseases and Sciences, 2012, 57 : 472 - 480
  • [46] Predictors of Response and Remission to Certolizumab Pegol in Patients With Crohn's Disease: Data From the WELCOME Study
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert R.
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Ernault, Etienne
    Fedorak, Richard N.
    Spehlmann, Martina
    Wolf, Douglas C.
    Lee, Scott D.
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2010, 138 (05) : S164 - S164
  • [47] Assessment of the Safety of Certolizumab Pegol Associated with the Time of Previous Biologic Treatment of Crohn's Disease at a Single North American Site
    Wheat, Chelle
    Ko, Cynthia
    Wahbeh, Ghassan
    Cullinan, Cory
    Etter, Scott
    Sinanan, Mika
    Lee, Scott
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S472 - S472
  • [48] HEALTHCARE SERVICE UTILIZATION AND COSTS OF CERTOLIZUMAB PEGOL VERSUS INFLIXIMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE
    Tkacz, Joseph
    Lee, Edward
    Low, Robert
    Stark, Jeffrey
    Yassine, Mohamed
    Brady, Brenna L.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S15 - S15
  • [49] Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis
    Ananthakrishnan, Ashwin N.
    Hur, Chin
    Korzenik, Joshua R.
    DIGESTIVE DISEASES AND SCIENCES, 2012, 57 (02) : 472 - 480
  • [50] HEALTHCARE SERVICE UTILIZATION AND COSTS OF CERTOLIZUMAB PEGOL VERSUS INFLIXIMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE
    Tkacz, Joseph
    Lee, Edward
    Low, Robert
    Stark, Jeffrey
    Yassine, Mohamed
    Brady, Brenna L.
    GASTROENTEROLOGY, 2018, 154 (01) : S22 - S22
12345